Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000358685 | SCV000344311 | uncertain significance | not provided | 2018-06-22 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000358685 | SCV002583968 | uncertain significance | not provided | 2023-12-15 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Fulgent Genetics, |
RCV002494889 | SCV002782409 | uncertain significance | Hypercholanemia, familial 1; Cholestasis, progressive familial intrahepatic, 4 | 2021-07-29 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002519330 | SCV003735452 | uncertain significance | Inborn genetic diseases | 2021-12-08 | criteria provided, single submitter | clinical testing | The c.2791G>A (p.A931T) alteration is located in exon 19 (coding exon 19) of the TJP2 gene. This alteration results from a G to A substitution at nucleotide position 2791, causing the alanine (A) at amino acid position 931 to be replaced by a threonine (T). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Mayo Clinic Laboratories, |
RCV000358685 | SCV005410724 | uncertain significance | not provided | 2024-01-05 | criteria provided, single submitter | clinical testing | BP4 |